CoQ10: Why use Vitaline® CoQ10?
Why use Vitaline® CoQ10?
It turns our there are many reasons to take Vitaline CoQ10.
You may have heard about CoQ10. In fact, you, or people you know may already supplement with it. But you may wonder why.
We all have some natural CoQ10 in the body
CoQ10 or “coenzyme Q10” is a natural, fat-soluble nutrient found in virtually all human cells. In fact, CoQ10’s other name is “ubiquinone” because it’s pretty much everywhere, or “ubiquitous.”
How does it work?
Inside each cell are structures called “mitochondria.” They have been described as “the cell within the cell” or as “cellular engines.”
Our cells need CoQ10 because it is crucial to helping our cellular engines—the mitochondria—produce energy. It’s not that CoQ10 is an “engine,” or even the fuel. It’s more like a spark plug, helping turn potential energy into real energy.
Which cells use CoQ10 the most?
Certainly all cells need energy, but think about two of the hardest working systems in your body—your heart and your mind. Understandably, CoQ10 is extremely important for our heart health—where vast amount of energy are required every day, all the time—but it’s also important to neurological health as well.†1,2 In fact, there has been strong research supporting CoQ10’s role in supporting neurological health, including critical concerns, for some time.†1-6 The important thing is finding a CoQ10 supplement that actually makes a difference.
CoQ10 supplements: the Vitaline® difference
CoQ10 supplements are available in natural and synthetic forms. A natural supplement (also called the “trans” form) is like the kind you already have in your body. It also has the most studies that support its safety and efficacy. A synthetic CoQ10 (also called the “cis” form) is similar, but structurally different from the natural form.
Vitaline contains the natural form of CoQ10, naturally.
Vitaline CoQ10 is derived from a yeast fermentation process, not from bacteria or plant matter. The Vitaline proprietary material has properties that improve absorption, bioavailability and safety.† No other CoQ10 product uses the same material or specifications.
The Blood-Brain Barrier
In order to reach the brain cells, CoQ10 must pass through what is called “the blood-brain barrier.” This unique structure is part of our natural defense system that restricts what can (and cannot) leave the bloodstream and enter the brain.
Most of the time, this is good. The blood-brain barrier protects the brain and spinal cord from potentially toxic substances. However, it can also be a significant obstacle to delivering beneficial nutrients to the central nervous system, especially when they are most needed.
Vitaline CoQ10 was the first to have proven absorption, and to be shown to increase mitochondrial levels of CoQ10, cross the blood brain barrier, and impact the health of users.†3
Benefits for many concerns
It’s not surprising that CoQ10 would have benefits that extend beyond that of neurological support, given its importance at a cellular level throughout the body. The chart below summarizes health concerns and appropriate supplemental levels:
Health Benefit
|
Supplement Level |
| Neurological Support†3-6 |
1200 mg – 2400 mg |
| Cranial Vascular Support†7,8 |
100 mg – 300 mg |
| Cardiovascular Support†9-16 |
100 mg – 250 mg |
| Cellular Health†17-19 |
100 mg – 200 mg |
| Reproductive Health†20,21 |
200 mg |
| Periodontal Health†22,23 |
200 mg |
| Musculoskeletal Health†24,25 |
100 mg |
| Blood Sugar Metabolism †16,26 |
50 mg — 200 mg |
Be informed
People supplement with CoQ10 for many health reasons. Unfortunately, many patients don’t discuss their choice of supplement with their doctor or health care practitioner. It’s important to choose a CoQ10 supplement that offers proof, not just promises.
Used in NIH- (National Institutes of Health) funded clinical trials, Vitaline® CoQ10 has been independently proven to be:
- Well absorbed†
- Safe at high supplementation
- Able to boost serum levels of CoQ10†
- Able to cross cell walls and the blood-brain barrier†3,4,27,28
In fact, there’s no contest as to which CoQ10 product has been proven most effective. To date, over 20 published studies have used Vitaline CoQ10 in their research.
Safety—part of the Vitaline difference
It’s important that your CoQ10 product isn’t causing you more harm than good. One common ingredient often used as a CoQ10 excipient – a substance that helps in the manufacturing of a product, but is not required to be listed as an ingredient – is propylene glycol. However, with Vitaline Coq10, everything that goes into the product is on the label.
At low doses, that may not be a problem. But, propylene glycol is toxic to nerves cells at very high doses.
Vitaline uses a proprietary fatty acid delivery system and contains no propylene glycol. It’s also available in multiple doses, forms and flavors.
Many individuals take CoQ10 at high doses for various reasons, yet most CoQ10 products have not been formulated for such a high daily dose. Vitaline CoQ10 has been proven to be safe at doses of up to 3000 mg a day.29 Tried and tested, it is the most trusted CoQ10 supplement available.
References
- Mitchell P. The vital protonmotive of coenzyme Q. In: Folkers K, Littarru GP, Yamagami T. Eds. Biochemical and Clinical Aspects of Coenzyme Q. Vol 6. Amsterdam: Elsevier Press; 1991:3-10.
- Sinatra ST, DeMarco J. Free radicals, oxidative stress, oxidized low density lipoprotein (LDL) and the heart: antioxidants and other strategies to limit cardiovascular damage. Conn Med. 1995;59:579-588.
- Matthews RT, Yang L, Browne S, Baik MF. Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proc Natl Acad Sci USA. 1998; 95:8892-8897.
- Shults CW, Oakes D, Kieburtz K, Beal MF, Haas R, Plumb S, Juncos JL, Nutt J, Shoulson I, Carter J, Kompoliti K, Perlmutter JS, Reich S, Stern M, Watts RL, Kurlan R, Molho E, Harrison M, Lew M; Parkinson Study Group. Effects of coenzyme Q10 in early Parkinson disease. Arch Neurol. 2002;59(10):1541-50.
- Shults CW, Flint Beal MD, Fontaine D, Nakeno K, Haas RH. Absorption, tolerability, and effects on mitochondrial activity of oral coenzyme Q10 in parkinsonian patients. Neurology.1998;50:793-795.
- Flint Beal. Neuroprotective strategies for treatment of lesions produced by mitochondrial toxins: implications for neurodegenerative diseases. Neuroscience. 1996;71:1043-1048.]
- Sandor PS, Di Clemente L, Coppola G, Saenger U, Fumal A, Magis D, Seidel L, Agosti RM, Schoenen J. Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial. Neurology. 2005;64(4):713-5.
- RD, Oshinsky ML, Gebeline CA, Bradley KC, Young WB, Shechter AL, Silberstein SD. Open label trial of coenzyme Q10 as a migraine preventative. Cephalalgia. 2002 ;22 :137-141.
- Folkers K, Langsjoen P, Willis R, Richardson P, Xia LJ, Ye CQ, Tamagawa H. Lovastatin decreases coenzyme Q levels in humans. Proc Natl Acad Sci U S A. 1990;87(22):8931-4.
- Ghirlanda G, Oradei A, Manto A, Lippa S, Uccioli L, Caputo S, Greco AV, Littarru GP. Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study. J Clin Pharmacol. 1993;33(3):226-9
- Morisco C, Trimarco B, Condorelli M. Effect of coenzyme Q10 therapy in patients with congestive heart failure: a long-term multicenter randomized study. Clin Investig.1993;71(8 Suppl):S134-6
- Singh RB, Wander GS, Rastogi A, Shukla PK, Mittal A, Sharma JP, Mehrotra SK, Kapoor R, Chopra RK. Randomized, double-blind placebo-controlled trial of coenzyme Q10 in patients with acute myocardial infarction. Cardiovasc Drugs Ther.1998;12(4):347-53
- Singh RB, Neki NS, Kartikey K, Pella D, Kumar A, Niaz MA, Thakur AS. Effect of coenzyme Q10 on risk of atherosclerosis in patients with recent myocardial infarction. Mol Cell Biochem. 2003;246(1-2):75-82.
- Digiesi V, Cantini F, Oradei A, Bisi G, Guarino GC, Brocchi A, Bellandi F, Mancini M, Littarru GP. Coenzyme Q10 in essential hypertension. Mol Aspects Med. 1994;15 Suppl:s257-63.
- Langsjoen PH, Langsjoen A, Willis R, Folkers K. Treatment of hypertrophic cardiomyopathy with coenzyme Q10. Mol Aspects Med. 1997;18:S145-S151.
- Hodgson JM, Watts GF, Playford DA, Burke V, Croft KD. Coenzyme Q10 improves blood pressure and glycaemic control: a controlled trial in subjects with type 2 diabetes. Eur J Clin Nutr. 2002;56(11):1137-42.
- Folkers K. Relevance of the biosynthesis of Coenzyme Q10 and the four bases of DNA as a rationale for the molecular causes of cancer and a therapy. Biochem Biophys Res Commun. 1996;224:358-361.
- Folkers K, Morita M, McRee J Jr. The activities of coenzyme Q10 and vitamin B6 for immune responses. Biochem Biophys Res Commun. 1993;193(1):88-92
- O, Ozakaya O, Erden Inal M, et al. Coenzyme Q10 concentrations and antioxidant status in tissues of breast cancer patients. Clin Biochem. 2000;33:279-284.
- Balercia G, Mosca F, Mantero F, Boscaro M, Mancini A, Ricciardo-Lamonica G, Littarru G. Coenzyme Q(10) supplementation in infertile men with idiopathic asthenozoospermia: an open, uncontrolled pilot study. Fertil Steril. 2004;81(1):93-8.
- Balercia G, Buldreghini E, Vignini A, Tiano L, Paggi F, Amoroso S, Ricciardo-Lamonica G, Boscaro M, Lenzi A, Littarru G. Coenzyme Q(10) treatment in infertile men with idiopathic asthenozoospermia: a placebo-controlled, double-blind randomized trial. Fertil Steril. 2008 Apr 5.
- Wilkinson EG, Arnold RM, Folkers K, Hansen I, Kishi H. Bioenergetics in clinical medicine. II. Adjunctive treatment with coenzyme Q in periodontal therapy. Res Commun Chem Pathol Pharmacol. 1975;12(1):111-23.
- Hansen IL, Iwamoto Y, Kishi T, Folkers K, Thompson LE. Bioenergetics in clinical medicine. IX. Gingival and leucocytic deficiencies of coenzyme Q10 in patients with periodontal disease. Res Commun Chem Pathol Pharmacol. 1976;14(4):729-38.
- Caso G, Kelly P, McNurlan MA, Lawson WE. Effect of coenzyme q10 on myopathic symptoms in patients treated with statins. Am J Cardiol. 2007;99(10):1409-12.
- Folkers K, Simonsen R. Two successful double-blind trials with coenzyme Q10 (vitamin Q10) on muscular dystrophies and neurogenic atrophies. Biochim Biophys Acta. 1995;1271(1):281-6.
- Singh RB, Niaz MA, Rastogi SS, Shukla PK, Thakur AS. Effect of hydrosoluble coenzyme Q10 on blood pressures and insulin resistance in hypertensive patients with coronary artery disease. J Hum Hypertens. 1999;13(3):203-8
- The Huntington Study Group. A Randomized, Placebo-Controlled Trial of Coenzyme Q10 and Remacemide in Huntington’s Disease. Neurology. 2001:57:397-404.
- Feigin A, Kieburtz K, Como P, Hickey C, Claude K, Abwender D, Zimmerman C, Steinberg K, Shoulson I. Assessment of coenzyme Q10 tolerability in Huntington's disease. Mov Disord. 1996;11(3):321-323.
- Ferrante KL, Shefner J, Zhang H, Betensky R, O'Brien M, Yu H, Fantasia M, Taft J, Beal MF, Traynor B, Newhall K, Donofrio P, Caress J, Ashburn C, Freiberg B, O'Neill C, Paladenech C, Walker T, Pestronk A, Abrams B, Florence J, Renna R, Schierbecker J, Malkus B, Cudkowicz M.Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS. Neurology. 2005;65(11):1834-1836.
Published June 30, 2010